Revenue Breakdown
Composition ()
No data
Revenue Streams
Insulet Corp (PODD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is U.S.Omnipod, accounting for 70.4% of total sales, equivalent to $497.10M. Other significant revenue streams include International Omnipod and Drug Delivery. Understanding this composition is critical for investors evaluating how PODD navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Insulet Corp maintains a gross margin of 72.22%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.46%, while the net margin is 12.40%. These profitability ratios, combined with a Return on Equity (ROE) of 19.68%, provide a clear picture of how effectively PODD converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PODD competes directly with industry leaders such as EXAS and ZBH. With a market capitalization of $18.49B, it holds a significant position in the sector. When comparing efficiency, PODD's gross margin of 72.22% stands against EXAS's 68.64% and ZBH's 63.24%. Such benchmarking helps identify whether Insulet Corp is trading at a premium or discount relative to its financial performance.
